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SUMMARY
Respiratory syncytial virus (RSV) infection produces more severe disease and increased
hospitalization rates in high-risk babies. The monoclonal antibody palivizumab oﬀers protection
against complications, and the ﬁrst of ﬁve monthly doses should be administered before the
onset of community RSV activity. However, the required real-time prediction of this onset is
problematic. We attempted to identify seasonal RSV patterns by retrospectively examining
10 years of laboratory reports for RSV and clinical episode reports for certain respiratory
presentations in both primary and secondary care. Analysis of hospital laboratory reports,
incidence of acute bronchitis in primary care, and hospital admissions for acute bronchitis and
bronchiolitis in young children revealed a consistent increase in RSV activity during week 43
each year. Promptly commencing prophylaxis during the second week of each October (week 42)
would precede the onset of the RSV season in the United Kingdom, and provide coverage until
its decline in mid-March.
Respiratory syncytial virus (RSV) is the most
common cause of lower respiratory tract infection in
young children; its manifestations include bronchio-
litis in infants/young children, and acute bronchitis in
older children [1, 2]. Approximately 80% of children
are infected by 2 years of age, but re-infection can
occur throughout life. RSV infection is the common-
est cause of hospitalization in children aged <1 year
[3], and it causes more severe disease in high-risk
infants. Early data suggest a possible association
between RSV infection in children with chronic lung
disease who were born prematurely, and chronic res-
piratory morbidity [4]. The UK Joint Committee
on Vaccination and Immunisation advises that the
RSV-monoclonal antibody, palivizumab, should be
oﬀered prophylactically to babies under 2 years of age
with severe chronic lung disease, who are on home
oxygen during the RSV season and on a case-by-
case basis for babies with rare conditions such as
multiple congenital abnormalities or severe immuno-
deﬁciency [5].
Thresholds for community inﬂuenza activity are
used to trigger the use of neuraminidase inhibitors in
high-risk patients [6, 7], although the intervention of
choice in these patients remains prevention through
vaccination. In contrast, RSV activity cannot be
employed in the same way to trigger the use of pali-
vizumab. Laboratory data are subject to reporting
delays, and therefore cannot be used for real-time
decision making. In addition, the ﬁrst dose of palivi-
zumab should be given prior to the onset of RSV
activity and there are limited data to support its use
beyond ﬁve doses at monthly intervals. Thus, waiting
until laboratory data indicate that RSV is circulating
risks starting therapy too late ; conversely, starting
therapy too far in advance of RSV activity risks giving
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the ﬁfth monthly dose too early to cover the end of the
RSV season. Timing the use of palivizumab would be
optimized by increasing clarity over the precise onset
of the RSV season.
This retrospective study aimed to identify patterns
in seasonal RSV activity by examining 10 years of
laboratory data on RSV isolations, the incidence of
acute bronchitis in primary care, and hospitalizations
for bronchiolitis/bronchitis in children aged<5 years.
Virological data sources were as follows: labora-
tory reports of positive RSV detections made to the
Health Protection Agency (HPA) from approxi-
mately 300 NHS/private hospital laboratories be-
tween 1994 and week 20 of 2004; laboratory reports
of RSV from community-derived virological sampling
undertaken by the Enteric, Respiratory and Neuro-
logical Virus Laboratory (ERNVL) between 1999
and 2004. Samples tested included nasopharyngeal
aspirates, nose/throat swabs, and bronchoalveolar
washings. Methods for RSV testing included antigen
detection by immunoﬂuorescence and nucleic acid
detection by polymerase chain reaction (PCR) assays,
but excluded viral culture. Denominators and, there-
fore, rates of conﬁrmed RSV could not be calculated
as criteria and thresholds for RSV testing vary be-
tween individual hospitals and individual GPs. It was,
therefore, not possible to determine the proportion of
symptomatic patients tested.
Clinical data sources comprised: Royal College
of General Practitioners (RCGP) sentinel practice
episode rates for inﬂuenza-like illness (ILI), acute
bronchitis and total respiratory disease (TRD) be-
tween 1994 and 2004; NHS Direct total call rates,
and percentage of calls assigned to ‘colds/ﬂu’ or
‘cough’ algorithms between 2001 and 2004; hospital
admissions based on age between 1993 and 2003
with a respiratory discharge diagnosis, obtained
from Hospital Episode Statistics (HES). Notably, the
RCGP episode rate did not include a speciﬁc category
for bronchiolitis.
These virological and clinical data were graphed
against each other by year to identify associations
which might predict the beginning and end of RSV
activity each season.
Hospital RSV samples were highly skewed towards
the very young (91% from children aged 0–4 years).
In contrast, although 5000 community specimens
were submitted during this time to ERNVL, only 8%
were obtained from children aged <5 years. This
was most probably due to diﬃculties in obtaining
samples from this age group in general practice, and
consequently ERNVL data proved of no value for the
study.
Associations were noted between hospital labora-
tory reports of RSV from patients aged 1 month to
4 years (by date of specimen) and both RCGP episode
rates for acute bronchitis and the number of hospital
admissions for acute bronchitis and bronchiolitis,
among children aged 0–4 years (Fig.). Complete data
from these three sources were available between
1998/99 and 2002/03 RSV seasons, and in each season
RCGP acute bronchitis episode rates rose above
250/100 000 population during the same week that
100 or more positive detections of RSV were made.
Hospital admissions rose rapidly 2–4 weeks after this
point was reached (Table). Laboratory reports of
RSV decreased below 50 per week after early March
(week 10), but episode rates for acute bronchitis
tended to ﬂuctuate without the same obvious decline.
No clear associations were apparent between episode
rates for ILI, TRD or NHS Direct data and either
community/hospital RSV laboratory reports (data
not shown).
In order to appreciate the signiﬁcance of the results
presented in this study, it is necessary to be clear
why laboratory data are unsuitable for making real-
time decisions about the onset of RSV activity. The
laboratory reports of RSV from private and NHS
laboratories represent positive detections only, with-
out denominators. Thus, it is not possible to assess the
proportion of specimens positive in any given week,
which is considered to be a more reliable indicator
of increasing activity than the number of positive
specimens alone. In addition, reporting delays of up
to several weeks prevent these data being used for
real-time decision making. Retrospective analyses
by date of specimen, as described in this study, are
possible and more accurately reﬂect the timing of
clinical illness. By combining hospital laboratory data
with community data on acute bronchitis in children
aged 0–4 years, the study demonstrates that an
obvious upsurge in RSV activity occurs during mid-
October each year (week 43). The timing of this
upsurge appears so consistent that we conclude it can
be used to advise clinicians about starting palivizu-
mab in high-risk babies and children.
If prophylaxis with palivizumab were to be started
promptly during the second week in October each
year (week 42), this would almost always be just
before the onset of RSV activity in the United
Kingdom. Subsequently, the last of ﬁve consecutive
monthly doses would be administered in the second
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week of February (week 6). This would provide
coverage until mid-March, by which time RSV
detections tend to have fallen back to low levels
with hospital admissions for acute bronchitis and
bronchiolitis declining substantially. There remains
only a small risk of infections outside the peak period
associated with low levels of background activity.
Finally, it should be borne in mind that our ﬁndings
apply to the United Kingdom and that parallel
analyses would be needed in order to correctly time
palivizumab prophylaxis in other countries.
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Table. Timing of increase in weekly episode rates for acute bronchitis, laboratory reports of RSV and hospital
admissions for bronchiolitis and bronchitis in children aged 0–4 years
Winter
season
Episode rate:
acute bronchitis (0–4 years)
RSV laboratory reports
from 300 laboratories
around the UK
(1 month to 4 years)
UK NHS Hospital
admissions: bronchitis
and bronchiolitis
(0–4 years)
Week no.
(in which
episode
rateo250)
GP episode rate
for acute bronchitis
that week (per
100 000 population)
Week no.
(in which
reports
>100)
Cases of
laboratory-
conﬁrmed RSV
that week
Week no.
(in which
admissions
>100)
No. of UK
NHS hospital
admissions
that week
1998/99 43 254 43 149 46 99
1999/00 42 293 42 144 45 125
2000/01 43 250 43 107 47 166
2001/02 45 271 45 133 47 104
2002/03 43 287 43 134 46 128
2003/04 43 251 47 143 n.a. n.a.
n.a., Not available.
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Fig. RCGP episode rates for acute bronchitis, laboratory reports of RSV received by HPA Centre for Infections, and
hospital admissions between 1998/1999 and 2002/2003.
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